Nachrichten zur MacroGenics Aktie

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…

MacroGenics stock target lifted to $29 on ASCO optimism By Investing.com

MacroGenics stock target lifted to $29 on ASCO optimism…

MacroGenics (MGNX) Q4 2023 Earnings Call Transcript

MGNX earnings call for the period ending December 31, 2023.…

MacroGenics, Inc. (MGNX) Q4 2023 Earnings Call Transcript

…

BTIG raies MacroGenics stock on cancer drug potential By Investing.com

BTIG raies MacroGenics stock on cancer drug potential…

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused…

MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on…

MacroGenics to Participate in Upcoming Investor Conference

ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing…

MacroGenics to Participate in Upcoming Investor Conference

ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on…

MacroGenics stock climbs 13% in wake of upgrade by Citi

…

MacroGenics gains as Citi upgrades to Buy By Investing.com

MacroGenics gains as Citi upgrades to Buy…

MacroGenics (MGNX) Q3 2023 Earnings Call Transcript

MGNX earnings call for the period ending September 30, 2023.…

MacroGenics, Inc. (MGNX) Q3 2023 Earnings Call Transcript

…

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing,…

MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused…

Why Shares of MacroGenics Are Jumping Thursday

The company announced second-quarter earnings....…

MacroGenics (MGNX) Q2 2023 Earnings Call Transcript

MGNX earnings call for the period ending June 30, 2023....…

MacroGenics (MGNX) Reports Q2 Loss, Misses Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 30.77% and 51.46%, respectively, for the quarter ended June 2023. Do the…

MacroGenics GAAP EPS of $0.92 beats by $1.43, revenue of $13.13M misses by $16.83M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing,…

MacroGenics (MGNX) Q1 2023 Earnings Call Transcript

MGNX earnings call for the period ending March 31, 2023....…

MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing…

MacroGenics (MGNX) to Report Q1 Results: Wall Street Expects Earnings Growth

MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on…

Form 8-K MACROGENICS INC For: Mar 22

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Incyte Gets FDA Approval of Zynyz, Triggers Milestone Payment to MacroGenics

Incyte Gets FDA Approval of Zynyz, Triggers Milestone Payment to MacroGenics...…

MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)

ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing…

What 4 Analyst Ratings Have To Say About Macrogenics

Latest Ratings for MGNX DateFirmActionFromTo Feb 2022CitigroupUpgradesNeutralBuy Feb 2022SVB LeerinkMaintainsOutperform Feb 2022BMO CapitalInitiates Coverage OnOutperform …

Why MacroGenics Stock Tumbled Today

The company had quite a comedown shortly after releasing its latest set of annual results....…

Why Shares of MacroGenics Climbed Thursday

The cancer-focused biotech delivered a strong earnings report....…

MacroGenics stock climbs ~10% as FY22 revenue rises beating estimates

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics (MGNX) Q4 2022 Earnings Call Transcript

MGNX earnings call for the period ending December 31, 2022....…

MacroGenics GAAP EPS of -$1.95 misses by $0.07, revenue of $151.94M beats by $1.88M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: Senior VP and General Counsel verkauft Aktien von MacroGenics im Wert von 32.393$

Peters, Jeffrey Stuart - Vorstand - Tag der Transaktion: 2023-03-10...…

MacroGenics expands license agreement with Synaffix

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K MACROGENICS INC For: Mar 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics Shares Drop 12% After Thursday Move Higher

MacroGenics Shares Drop 12% After Thursday Move Higher...…

Why Shares of MacroGenics Jumped Thursday

The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy....…

MacroGenics Shares Rise 16% After Sale of Tzield Royalty Interest

MacroGenics Shares Rise 16% After Sale of Tzield Royalty Interest...…

MacroGenics unloads TZIELD royalty stake for up to $200M to a unit of DRI

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million

ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing…

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing…

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on…

Strength Seen in MacroGenics (MGNX): Can Its 25.7% Jump Turn into More Strength?

MacroGenics (MGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…

Insiderhandel: Insider kauft Aktien von MacroGenics im Wert von 2.532.600$

Biotech, Target N V. - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2023-02-14...…

MacroGenics phase 1 prostate cancer asset data leads to phase 2 initiation later in 2023

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium

ROCKVILLE, MD, Feb. 13, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on…

dpa-AFX ProFeed